Skip to main content
. 2020 Sep 23;39(20):e104514. doi: 10.15252/embj.2020104514

Figure 2. Mettl3 or Mettl14 deficiency enhances tumor‐infiltrating CD8+ T cells and cytokine production.

Figure 2

  • A
    Percentage of tumor‐infiltrating T cells, Treg, and NK cells were identified by flow cytometry from CT26 tumors as indicated. Each spot represents one mouse. *P < 0.05; **P < 0.01 by Student's t‐tests.
  • B
    Representative images of CD8 by IHC staining. Tissue sections from BALB/c mice bearing the indicated knockout of genes with treatment of PD1 antibody. Scale bars, 50 μm.
  • C
    Percentage of granzyme B‐expressing CD8+ T cells from control and Mettl3‐ or Mettl14‐deficient CT26 tumors. Each spot represents one mouse. *P < 0.05; **P < 0.01 by Student's t‐tests.
  • D, E
    Mice bearing control and Mettl3 or Mettl14 null tumors were treated with CD8‐depleting antibody and PD‐1 antibody or PD‐1/GVAX as indicated. Tumor volume was measured over time points. n, the numbers of mice. *P < 0.05; **P < 0.01; ***P < 0.001 by Student's t‐tests.
  • F, G
    IFN‐γ production in serum (F) and intratumor (G) from BALB/c mice by ELISA. The results are representatives of at least three independent experiments. n, the numbers of mice. Data are mean ± SEM. *P < 0.05 by Student's t‐tests.